Experts Publish First Guidance on Use of Teprotumumab for Thyroid Eye Disease

Teprotumumab, a disease-modifying therapy, is currently the only FDA-approved drug for  thyroid eye disease (TED). Despite being available since 2020, there are no guidelines to optimize its use in clinical practice. To address this gap, an expert panel came to a consensus on teprotumumab treatment recommendations, including when to initiate treatment, pretreatment considerations, monitoring throughout treatment, and strategies for mitigating and managing treatment-related adverse effects.

Upon completion of the educational activity, participants should be able to:

• Manage patients with TED who are candidates for or are treated with an FDA-approved disease-modifying therapy

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com